Document resource
Objectives To identify whether low lupus disease activity status on BEL is an achievable goal in cSLE.To describe the characteristics of cSLE patients treated with BEL in real world practice included in the JULES registry, a Spanish multicenter, hospital-based, cSLE registryMethods We analyzed cross-sectional data from 67 patients treated with BEL for cSLE from a total of 250 included in the JULES registry.For the description of the cohort, summary statistics of central tendency and dispersion and percentage statistics were used for numerical and categorical variables respectivelyResults 67 patients (26.8%) of the 250 patients included in the JULES registry were treated with BEL. The mean age to diagnosis was 12.9 years, with a mean age at inclusion in the registry of 20.4. 86.6% were female. LN prevalence was 56.1%, arthritis was seen in 74.6% and the most common laboratory abnormalities were leucopenia 68.2%, anti-DNA (89.6%) and hypocomplementemia (94%). The most frequent LN class was IV (23.9%),The main reasons for BEL initiation were arthritis (44.8%), mucocutaneous manifestations (40.3%), systemic manifestations (37.3%), LN (26.9%) and hematological involvement (22.4%).14 (20.9%) patients initiated BEL in the first 6 months of the disease and median time to belimumab treatment was less than 2 years (22.2 months).The mean duration of BEL treatment was 27.78 months (31.65). The mean SLEDAI and SLICC scores were 3.11 (2.12) and 0.46 (1.25) points respectively. 19.4% of BEL-treated patients have inactive disease (SLEDAI 0-1), 70.1% low disease activity (SLEDAI 2- 5), and 10.4% moderate activity. In patients with LN, 32.8% achieved complete remission and 10,4% partial remission, 4.5% experienced an improvement 74.6% had managed to completely withdraw prednisone .77.6% were still on BEL treatment.Conclusions In the Spanish cSLE registry (JULES), 28.9% of patients were treated with BEL. BEL was introduced in the first 6 months of the disease in 20.9% of patients and in the first 2 years in most of them (median time to BEL 22.2 months).In this complex and severe population, BEL is an effective and safe treatment for cSLE, allowing to achieve low disease activity state and corticosteroid withdrawal.